HealthPharma & Biotech
Circassia Pharmaceuticals PLC

Circassia enters pivotal week with two big FDA decisions due

By Sunday, Circassia will know whether its Duaklir COPD inhaler has been approved for sale in the US and whether Tudorza's supplemental NDA has been given the thumbs-up

man coughing
Regulators have been reviewing the two drugs for the past ten months

Circassia Pharmaceuticals PLC (LON:CIR) shares edged higher on Monday ahead of what looks set to be a pivotal week for the junior drug developer.

After ten months of analysis and reviews, the company will know whether US regulators have approved its Duaklir chronic obstructive pulmonary diseases (COPD) drug by 31 March.

It will also have found out about a supplemental new drug application (NDA) for Tudorza, another COPD drug it acquired from Astra two years ago.

READ: Circassia coughs up US$32mln for PPHN drug

The US is arguably the world’s most important and lucrative pharma industry, so the Food and Drug Administration’s (FDA) decisions are undoubtedly important.

There is plenty of competition in the US COPD market, but if Duaklir can secure even a slither of it, it would likely add tens of millions every year to Circassia’s top-line.

The inhaler already generates almost US$100mln a year for AstraZeneca PLC (LON:AZN), and that’s obviously without any sales in the US, where COPD is the third biggest killer that affects more than 10mln people.

AstraZeneca investors will also be keeping an eye out on the decisions as the pharma giant will receive a US$100mln pay-out should Duaklir gets the thumbs-up.

Positive data from two Phase III studies, as well as exacerbation data from another late-stage trial support the new drug application (NDA), so bosses are, as ever, upbeat about the drug’s prospects.

Initial decision not everything – ask Motif Bio

But even if the worst does happen, and there is no evidence to suggest it will, can Circassia take heart from Motif Bio PLC’s (LON:MTFB) recent disappointment?

Last month, the FDA rejected Motif’s NDA for its iclaprim antibiotic, saying that it required more data.

But AIM-quoted Motif asked for talks to iron out the issues and the pair are now meeting in a few weeks.

The company remains upbeat about its drug prospects. It is not going there merely for an explanation, it hopes the talks will help determine “the best way to move iclaprim towards marketing approval”.

Circassia shares were up just over 1% to 33.5p on Monday.

Quick facts: Circassia Pharmaceuticals PLC

Price: £0.18

Market: LSE
Market Cap: £66.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals PLC named herein, including the promotion by the Company of Circassia Pharmaceuticals PLC in any Content on the Site,...



Motif Bio announces US FDA approval deadline for its antibiotic drug

Motif Bio (LON:MTFB, NASDAQ: MTFB) CEO Graham Lumsden tells Proactive Investors the US FDA has begun the process of assessing whether the company’s next-generation antibiotic should be allowed to go on sale in the US. Motif's drug iclaprim has been granted a priority review by the...

on 08/15/2018


Holding(s) in Company

2 days, 22 hours ago

Holding(s) in Company

3 days, 22 hours ago

Holding(s) in Company

3 days, 22 hours ago

Holding(s) in Company

5 days, 3 hours ago

Holding(s) in Company

5 days, 4 hours ago

Holding(s) in Company

5 days, 23 hours ago

Block listing Interim Review

1 week, 2 days ago

2 min read